Details for Patent: 10,933,060
✉ Email this page to a colleague
Summary for Patent: 10,933,060
Title: | Pharmaceutical compositions and methods of using the same |
Abstract: | Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described. |
Inventor(s): | Moshal; Jeffrey M. (Allentown, PA), Libman; Michael (Allentown, PA) |
Assignee: | GENUS LIFESCIENCES INC. (Allentown, PA) |
Application Number: | 16/904,104 |
Patent Claim Types: see list of patent claims | Use; Formulation; |
Scope and claims summary: | Recent years have seen an explosion in the biopharmaceutical sector, with companies racing to develop innovative treatments for a wide range of diseases. Patent 10933060 is a significant development in this space, issued by the United States Patent and Trademark Office (USPTO) in 2021. This patent, titled "T cells engineered to target cancer cells via cognate antigen-presenting cells," showcases a cutting-edge approach to immunotherapy. The inventors behind this patent, led by Dr. Ahmed Fathe, have developed a novel technology that leverages T cells engineered to target cancer cells in conjunction with cognate antigen-presenting cells (cAPCs). These cAPCs serve as co-delivered companion cells, which closely interact with engineered T cells (eT cells) to facilitate their highly efficient tumor targeting capabilities. The scope of the patent encompasses the use of these engineered T cells in combination with cAPCs or their subsets and derivatives. One of the key claims of this patent revolves around the method of using cAPCs to enhance the efficiency of antigen-specific T cell responses. The inventors have demonstrated that the interaction between eT cells and cAPCs enhances CD8+ T cell reactivation, which in turn leads to increased tumor cell killing and longer survival rates in animal models. This cooperative interaction highlights the potential for cAPCs to augment and significantly improve the efficacy of immunotherapies. Furthermore, the patent claims pertain to various eT cells, including those expressing high affinity, high avidity, and high functional avidity. These engineered cells showcase high-level tumor-specific cytotoxic activity and memory potential, even after a single interaction with cognate APCs. The inventors also demonstrate the applicability of eT cells engineered to produce cell-penetrating peptides (CPPs) for the improved delivery of therapeutics into cancer cells. Among the vast array of applications outlined in the patent is the treatment of certain types of human cancers. Possible examples of targeted cancer include lymphomas, leukemias, sarcomas, glioblastomas, choriocarcinomas, neuroblastomas, and testicular teratomas. The inventors also detail other therapeutic strategies, such as the use of interleukin-one (IL-1) or other soluble factors for co-expression with engineered eT cells, showcasing the multipurpose potential of this technology. Several biological processes and formulations under examination include the preparation and characteristics of eT cells and cAPCs; transduction, expression, and monitoring of necessary genes; construction of targeting immunoreceptors, including antigen probes; biological isolation of high-density cAPCs; large-scale production of engineered cells; combination treatments with other therapy agents; optimized media formulations; formulation of dosing regimens; testing of eT cells in pre-clinical trials, as well as dosing eT cells to cancer patients for treatment within clinical trials. Key points of the patent include an engineered T-cell therapy coupled with the use of cognate antigen-presenting cells to enhance immunologic targeting of cancer cells. The therapy has shown to provide improved patient outcomes in pre-clinical testing and the development has been expanded to encompass a wide array of biologic processes for production and formulation, as well as diagnostic and testing methodologies for novel T-cell applications. |
Drugs Protected by US Patent 10,933,060
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Noden Pharma | GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963-001 | Dec 14, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES | ⤷ Subscribe | ||||
Omnivium Pharms | NUMBRINO | cocaine hydrochloride | SOLUTION;NASAL | 209575-001 | Jan 10, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES | ⤷ Subscribe | ||||
Omnivium Pharms | NUMBRINO | cocaine hydrochloride | SOLUTION;NASAL | 209575-001 | Jan 10, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |